Clinical trial NCT01646554: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Official title: BOS3: Randomized Phase II/III Trial Evaluating the Efficacy of FOLFOX Alone Versus FOLFOX Plus Aflibercept in K-ras Mutant as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Colorectal Cancer Metastatic
Liver Metastases
KRAS Mutated Colorectal Cancer
Keywords: Liver metastases
Colorectal Cancer
KRAS mutated
FOLFOX
Aflibercept
Randomized
Phase II-III
Perioperative treatment
Adjuvant
Neo-adjuvant
Surgery
Progression Free Survival
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sponsor class: NETWORK
Collaborators: name: Sanofi
First posted: 2012-07-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases, resection should be considered after limited chemotherapy.

There is consensus for a backbone chemotherapy consisting of fluoropyrimidine + oxaliplatin. FOLFOX was used in the previous EORTC study and is again recommended.

The addition of targeted agents to standard chemotherapy in the perioperative strategy for mCRC might increase the ORR and R0 resectability, without significant increase in toxicity, therefore translating to a better outcome.

BOS2 (EORTC 40091) was designed to test this hypothesis in patients with a KRAS wold-type profile.

It was decided in parallel to design an open label, randomized, multi-center, 2-arm phase II-III study this time aimed at enrolling KRAS mutated patients.

Arm A: (standard) mFOLFOX6 + Surgery Arm B: (experimental) mFOLFOX6 + Aflibercept + Surgery


Eligibility criteria: Inclusion Criteria:

* Histologically proven CRC with 1 to 8 metachronous or synchronous liver metastases considered to be completely resectable
* Primary tumor (or liver metastasis) of CRC must be KRAS status "mutant"
* Patients must have undergone complete resection (R0) of the primary tumor at least 4 weeks before randomization. Or for patients with synchronous metastases the primary tumor can be resected (R0) at the same time as the liver metastases if: the patient has a non-obstructive primary tumor and is able to receive preoperative chemotherapy (3-4 months) before surgery1.
* Measurable hepatic disease by RECIST version 1.1
* Patients must be 18 years old or older
* A World Health Organization (WHO) performance status of 0 or 1
* Previous adjuvant chemotherapy for primary CRC is allowed if completed at least 12 months before inclusion in this study
* All the following tests should be done within 4 weeks prior to randomization:
* Hematological status: neutrophils (ANC) = 1.5x10 9/L; platelets = 100x10 9/L; haemoglobin = 9g/dL
* Serum creatinine = 1.5 times the upper limit of normal (ULN)
* Proteinuria \< 2+ (dipstick urinalysis) or =1g/24hour.
* Liver function: serum bilirubin = 1.5 x upper normal limit (ULN), alkaline phosphatase \< 5xULN
* Magnesium ≥ lower limit of normal (LLN)
* Patients with a buffer range from the normal values of +/- 5% for hematology and +/- 10% for biochemistry are acceptable. This will not apply for Renal Function, including Creatinine.
* Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 14 days prior to the first dose of study treatment.
* Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
* Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
* Patient should be willing and able to comply with protocol requirements
* Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

* Evidence of extra-hepatic metastasis (of CRC)
* Previous chemotherapy for metastatic disease or surgical treatment (e.g. surgical resection or radiofrequency ablation) for liver metastasis. Radiotherapy alone is allowed if given pre or post protocol treatment
* Previous exposure to VEGF/VEGFR targeting therapy within the last 12 months
* Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization
* Gilbert's syndrome
* History of myocardial infarction and/or stroke within 6 months prior to randomization
* Uncontrolled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \> 100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy
* History or evidence upon physical examination of CNS metastasis
* Bowel obstruction
* Uncontrolled hypercalcemia
* Pre-existing permanent neuropathy (NCI grade = 2)
* Known allergy to any excipient to study drugs

Primary outcomes:
measure: Progression free survival
timeFrame: 1 year
Secondary outcomes:
measure: Pathological response rate
timeFrame: 4 years
measure: Resection rate
timeFrame: 4 years
measure: Overall survival
timeFrame: 8 years
measure: Safety
timeFrame: 4 years
Other outcomes:
Locations:
Study officials:
affiliation: C.H.U. AMBROISE PARE AP-HP, Boulogne-Billancourt, France
name: Bernard Nordlinger, Pr.
role: STUDY_CHAIR
References: